State of care for hemophilia in pediatric patients (Q34574267)

3 August 2017

1 reference

title

State of care for hemophilia in pediatric patients (English)

1 reference

3 August 2017

0 references

Pier Mannuccio Mannucci

series ordinal

3

object named as

Pier M Mannucci

1 reference

3 August 2017

Elena Santagostino

1

1 reference

3 August 2017

Alessandro Gringeri

series ordinal

2

1 reference

3 August 2017

publication date

1 January 2002

1 reference

3 August 2017

1 reference

3 August 2017

volume

4

1 reference

3 August 2017

issue

3

1 reference

3 August 2017

page(s)

149-157

1 reference

Treatment of hemophilia A with a highly purified factor VIII concentrate prepared by anti-FVIIIc immunoaffinity chromatography

3 August 2017

cites work

1 reference

12 December 2020

Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial

1 reference

12 December 2020

Clinical experience with recombinant factor VIIa

1 reference

12 December 2020

Haemophilia prophylaxis in young patients--a long-term follow-up

1 reference

12 December 2020

Adverse effects of treatment with porcine factor VIII.

1 reference

12 December 2020

Acute hepatitis A in patients with haemophilia A.

1 reference

12 December 2020

A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group

1 reference

12 December 2020

A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate

1 reference

12 December 2020

1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases

1 reference

12 December 2020

Immune tolerance in hemophilia-principal results from the International Registry. Report of the factor VIII and IX Subcommittee.

1 reference

12 December 2020

The natural history of factor VIII:C inhibitors in patients with hemophilia A: a national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors

1 reference

12 December 2020

The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO).

1 reference

12 December 2020

Hemophilia in the First Year of Life

1 reference

12 December 2020

Considerations for current and future management of haemophilia and its complications

1 reference

12 December 2020

Prospective multicenter study on subcutaneous concentrated desmopressin for home treatment of patients with von Willebrand disease and mild or moderate hemophilia A

1 reference

12 December 2020

Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate

1 reference

12 December 2020

Induced immunotolerance in factor VIII inhibitor patients.

1 reference

12 December 2020

Nasal spray desmopressin (DDAVP) for mild hemophilia A and von Willebrand disease

1 reference

12 December 2020

Disappearance of factor VIII:C antibodies in patients with haemophilia A upon frequent administration of factor VIII in intermediate or low dose

1 reference

12 December 2020

Low risk of viral infection after administration of vapor-heated factor VIII concentrate. International Investigator Group

1 reference

12 December 2020

Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: the advantages of early intervention

1 reference

12 December 2020

A prospective clinical trial of implantable central venous access in children with haemophilia

1 reference

12 December 2020

Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs

1 reference

12 December 2020

Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group

1 reference

12 December 2020

Suggestions for the management of factor VIII inhibitors

1 reference

12 December 2020

Effect of dry-heating of coagulation factor concentrates at 80 degrees C for 72 hours on transmission of non-A, non-B hepatitis. Study Group of the UK Haemophilia Centre Directors on Surveillance of Virus Transmission by Concentrates

1 reference

12 December 2020

Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. The Italian Collaborative Group

1 reference

12 December 2020

Eliminating parvovirus B19 from blood products

1 reference

12 December 2020

GUIDELINES ON THERAPEUTIC PRODUCTS TO TREAT HAEMOPHILIA AND OTHER HEREDITARY COAGULATION DISORDERS.

1 reference

12 December 2020

Low risk of transmission of the human immunodeficiency virus by a solvent-detergent-treated commercial factor VIII concentrate

1 reference

12 December 2020

Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B.

1 reference

12 December 2020

Accelerated schedule of hepatitis B vaccination in patients with hemophilia.

1 reference

12 December 2020

Use of central venous catheters in children with severe congenital coagulopathy

1 reference

12 December 2020

Absence of anti-human immunodeficiency virus types 1 and 2 seroconversion after the treatment of hemophilia A or von Willebrand's disease with pasteurized factor VIII concentrate

1 reference

12 December 2020

Guidelines on replacement therapy for haemophilia and inherited coagulation disorders in Italy

1 reference

12 December 2020

Low risk for hepatitis C in hemophiliacs given a high-purity, pasteurized factor VIII concentrate. International Study Group

1 reference

12 December 2020

Patterns of immunogenicity of an inactivated hepatitis A vaccine in anti-HIV positive and negative hemophilic patients

1 reference

12 December 2020

A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group

1 reference

12 December 2020

Management of haemophilia B patients with inhibitors and anaphylaxis

1 reference

12 December 2020

Human parvovirus B19 infection in hemophiliacs first infused with two high‐purity, virally attenuated factor Vlll concentrates

1 reference

12 December 2020

Factor VIII inhibitors. Etiology, characterization, natural history, and management

1 reference

12 December 2020

Acute myocardial infarction following administration of recombinant activated factor VII (Novo Seven) in a patient with haemophilia A and inhibitor

1 reference

12 December 2020

Myocardial infarction complicating activated prothrombin complex concentrate substitution in patient with hemophilia A.

1 reference

12 December 2020

Complications of indwelling venous access lines in the pediatric hematology patient: a prospective comparison of external venous catheters and subcutaneous ports.

1 reference

12 December 2020

10.2165/00128072-200204030-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

3 August 2017

1006718488

0 references

1 reference